JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax

Eli Lilly is reportedly looking to acquire French biotech Abivax, sending the latter company’s shares surging ahead of the J.P. Morgan Healthcare Conference 2026. According to a report by French news outlet La Lettre on 12 January, Eli Lilly is said to be working on a potential €15bn ($17.5bn) deal for Abivax, a company developing anti-inflammatory drugs. Eli Lilly declined to comment on business development activity, and Abivax did not immediately respond to Pharmaceutical Technology's request regardin ...